FDA approves Zyogreen, a ready-to-use indocyanine green for surgical imaging
Cleared on 10 July under NDA 218579, the Provepharm agent fluoresces in near-infrared light to map vessels, perfusion and lymph nodes during surgery. Efficacy rests on studies of an earlier formulation.
| Group | Value (%) |
|---|---|
| Indocyanine green | 93 |
| Blue dye | 43 |
The Food and Drug Administration has approved Zyogreen, a ready-to-use injectable form of indocyanine green, an optical dye that surgeons use to see structures the naked eye cannot. The approval was recorded in Drugs@FDA on 10 July 2026 under new drug application 218579, held by Provepharm SAS and reviewed on the agency's standard track [s1]. The product is a sterile solution containing 25 mg of indocyanine green in 10 mL, a concentration of 2.5 mg/mL, for intravenous or interstitial use [s1].
Indocyanine green is an old molecule with a long clinical history. What Zyogreen adds is a ready-to-use, pre-mixed presentation of it from a new manufacturer, rather than a new imaging mechanism.
What it does
The dye works in the near-infrared range. When bound to proteins in blood or lymph, indocyanine green absorbs near-infrared light with a peak at 805 nm and re-emits fluorescence at a slightly longer wavelength, peaking at 830 nm [s2]. A fluorescence camera supplies the excitation light and renders the returning glow as a live image on a monitor, so a surgeon can watch blood flow into tissue, trace vessels, or pick out lymph nodes in real time [s2].
The approved uses are broad. The label covers fluorescence imaging of vessels, blood flow and tissue perfusion before, during and after vascular, gastrointestinal, organ-transplant, plastic, and micro- and reconstructive surgery, including minimally invasive procedures [s2]. Separate sections of the label cover lymphatic mapping in cervical and uterine cancer and visualisation of the extrahepatic bile ducts [s2]. Dosing is small and setting-specific — for perfusion imaging, adults and children a month or older receive 1.25 mg to 5 mg by intravenous injection [s2].
The evidence for cancer lymph-node mapping
As with many reformulations, the effectiveness of Zyogreen was established on a study of another indocyanine green formulation rather than on fresh trials of this exact product [s2]. The cancer-mapping indication rests on the FILM study (NCT02209532), a randomised, prospective, multi-centre, open-label trial in patients with early-stage uterine or cervical cancer and no clinically evident spread [s2].
FILM randomised 176 patients to receive indocyanine green and a blue dye comparator in either order, injected into the cervix at the start of surgery [s2]. Each patient received four 1 mL injections of a 1.25 mg/mL solution — a total dose of 5 mg — placed at the 3 o'clock and 9 o'clock positions, with a shallow and a deep injection at each [s2]. Surgeons then mapped and removed the highlighted tissue, and pathologists confirmed which specimens were true lymph nodes [s2].
Among the histologically confirmed lymph nodes, 93% were identified using indocyanine green and 43% using the blue dye — a difference of 50 percentage points (95% confidence interval 39% to 60%) [s2]. The patients had a mean age of 63 years, ranging from 31 to 88 [s2]. The comparison is the clearest quantitative signal in the label, and it is a direct head-to-head against the older tracer surgeons have long relied on.
Safety to note
The label's central caution is allergy. Hypersensitivity reactions — including anaphylaxis, urticaria and deaths from anaphylaxis — have been reported after intravenous indocyanine green, and the drug is contraindicated in anyone with a known hypersensitivity to it [s2]. The label instructs that resuscitation personnel and equipment be on hand and that patients be monitored during use [s2]. The formulation also contains a small amount of sodium iodide, a point relevant to patients with iodide sensitivity [s2].
How to read it
For operating teams, the practical meaning is another supply of a familiar tool, in a pre-mixed form that removes a reconstitution step. The FILM result is a genuine efficacy signal, but it was generated with an earlier indocyanine green formulation, and it speaks to one procedure — cervical and uterine cancer node mapping — not to every use the broad label permits. The dye shows where structures are; it does not by itself tell a surgeon what the tissue is, which is why excised nodes are still confirmed under the microscope.
This article describes a regulatory approval and is not medical advice. Decisions about surgical imaging are for clinicians and their patients. Patients with a history of reactions to indocyanine green or to iodide products should tell their surgical team before any procedure that uses the dye.
Sources
- Drugs@FDA: Zyogreen (indocyanine green), NDA 218579 — approval record — U.S. Food and Drug Administration (openFDA drug/drugsfda API) , July 10, 2026
- Zyogreen (indocyanine green injection) — US prescribing information — U.S. Food and Drug Administration (openFDA drug/label API) , July 16, 2026
More on
FDA clears Navitrux, an intravenous fosaprepitant, for chemotherapy nausea
Approved on 24 June under NDA 220436, the Avyxa Holdings product is a ready-to-infuse form of the NK-1 blocker fosaprepitant, cleared on studies of an earlier intravenous version of the drug.
FDA firms up Keytruda's tumour-mutation approval and raises the cutoff
On 16 October the FDA converted pembrolizumab's accelerated approval for mutation-heavy solid tumours to full approval, but narrowed it: the qualifying threshold moved from 10 to 13 mutations per megabase.
A 10-year trial finds radiotherapy cuts atypical meningioma recurrence after surgery
ROAM/EORTC-1308, an independent phase 3 trial, randomised 157 patients after complete brain-tumour removal; adjuvant radiotherapy improved five-year disease-free survival, but the benefit's confidence interval was wide.
FDA clears subcutaneous Rybrevant Faspro for recurrent head and neck cancer
The agency gave accelerated approval on 5 November to amivantamab and hyaluronidase-lpuj for recurrent or metastatic head and neck squamous cell carcinoma after platinum chemotherapy and a PD-1 drug. Response rate: 42%.